✦ LIBER ✦

Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C

✍ Scribed by Henry L. Y. Chan; Hong Ren; Wan C. Chow; Theodore Wee

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 286 KB
Volume: 46
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21683

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of chronic hepatitis C with co

Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial

✍ M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 2 views

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC

Hepatitis C Virus p7 membrane protein qu

Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine

✍ S. Castelain; D. Bonte; F. Penin; C. François; D. Capron; S. Dedeurwaerder; P. Z 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

## Abstract A clinical study was carried out to compare the response rate of two groups of non‐responder (NR) hepatitis C virus (HCV) genotype 1 chronically infected patients treated with interferon and ribavirin, with or without amantadine. The viral load decreased more markedly in the group treat

Sequential versus concomitant administra

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial

✍ Raffaello Sostegni; Valeria Ghisetti; Fabrizia Pittaluga; Giovanna Marchiaro; Gi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

We conducted a three-arm, randomized trial in 96 patients with chronic hepatitis C who did not respond to interferon alfa to compare treatments. Group 1 (33 patients) received ribavirin alone (1,000 mg/daily for 6 months) followed by interferon alfa n-3 alone (3 MU thrice weekly for 6 months); group

Peginterferon alfa-2b and weight-based o

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

✍ Ira M. Jacobson; Robert S. Brown Jr; Bradley Freilich; Nezam Afdhal; Paul Y. Kwo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

Clifford A. Brass, 15 and the WIN-R Study Group This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults with

Response to higher doses of interferon a

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial

✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

Lymphoblastoid interferon alfa with or w

Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: A multicenter controlled trial

✍ G V Gregorio; P Jara; L Hierro; C Diaz; A de la Vega; A Vegnente; R Iorio; F Bor 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 1 views

## Steroid priming does not potentiate the effect of IFN-a. The comparative efficacy of prednisolone followed by (HEPATOLOGY 1996;23:700-707.) interferon alfa (IFN-a) versus IFN-a alone in enhancing the rate of antibody to hepatitis B e antigen (anti-HBe) seroconversion has not been evaluated in a